Fast Track designation is a positive de-risking event for the SSc-RP pipeline, but the Phase 2a study has not yet started and approval is years away. Monitor enrollment and data from the RE-WARM study (expected Q4 2026 start) for the next meaningful catalyst. The existing PAH/PH-ILD commercial business provides a floor, but SSc-RP upside is speculative at this stage.
Price Chart
Executive Summary
No summary provided
Key Facts
- FDA granted Fast Track designation to YUTREPIA for SSc-RP, a condition with no approved U.S. therapy.
- Liquidia estimates the addressable U.S. population of moderate-to-severe SSc-RP patients at approximately 30,000.
- Phase 2a RE-WARM study (NCT07748000) expected to begin October 2026 with primary completion targeted for February 2027.
- Fast Track designation enables more frequent FDA interactions, potential rolling review, and eligibility for Priority Review or Accelerated Approval.
- YUTREPIA is already approved for PAH and PH-ILD, providing an existing commercial base.
Financial Impact
Fast Track designation is a procedural milestone with no direct financial impact. The addressable SSc-RP market is estimated at ~30,000 U.S. patients, but no revenue timeline is established.
Risk Factors
- Fast Track designation does not guarantee FDA approval; clinical trial failure or safety issues could halt development.
- Phase 2a study is small (75 patients) and open-label; results may not be predictive of Phase 3 outcomes.
- Competing therapies for SSc-RP may emerge, and the market size (~30,000 patients) is modest.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3355783 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 8-K | $33.94 $34.78 | ▲ +2.48% | ▲ +2.19% | $43.74 (+28.87%) |
Oct 13, 2026 13d ago | Insider Cluster | $33.94 $34.78 | ▲ +2.48% | ▲ +2.19% | $43.74 (+28.87%) |
Sep 30, 2026 26d ago | 8-K | $27.99 $28.64 | ▼ −2.32% | ▼ −1.58% | $43.74 (−56.27%) |
Sep 3, 2026 7w ago | 8-K | $68.63 $68.66 | ▲ +0.04% | ▲ +0.43% | $43.74 (−36.27%) |
Sep 3, 2026 7w ago | Press Release | $68.63 $68.66 | ▲ +0.04% | ▲ +0.43% | $43.74 (−36.27%) |
Aug 25, 2026 8w ago | Insider Cluster | $71.36 $69.94 | ▼ −1.99% | ▼ −2.65% | $43.74 (−38.71%) |
Aug 21, 2026 9w ago | Insider Cluster | $70.27 $70.49 | ▲ +0.31% | ▼ −0.01% | $43.74 (−37.75%) |
Aug 12, 2026 10w ago | 8-K | $78.79 $72.10 | ▼ −8.49% | ▼ −9.19% | $43.74 (−44.49%) |
Aug 12, 2026 10w ago | Press Release | $78.79 $72.10 | ▲ +8.49% | ▲ +9.19% | $43.74 (+44.49%) |
Jul 29, 2026 12w ago | Insider Cluster | $86.80 $84.11 | ▼ −3.10% | ▼ −3.82% | $43.74 (−49.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers